Recalibrating Dual Checkpoint Blockade? Lessons from Volrustomig.

Area of Science:

• Immunotherapy
• Oncology
• Drug Development

Background:

• Dual immune checkpoint blockade targeting PD-1 and CTLA-4 enhances anti-tumor immunity.
• Toxicity associated with combined PD-1/CTLA-4 inhibition can limit clinical application.
• Novel therapeutic formats are needed to improve the efficacy and safety of dual blockade.

Purpose of the Study:

• To evaluate the safety and efficacy of volrustomig, a novel bispecific antibody targeting PD-1 and CTLA-4.
• To assess the therapeutic index of a bispecific antibody format for dual immune checkpoint inhibition.
• To identify key considerations for future clinical development of volrustomig.

Main Methods:

• First-in-human (FIH) clinical study design.
• Dose-escalation and dose-expansion cohorts.
• Assessment of anti-tumor responses using RECIST criteria.
• Monitoring of immune-related adverse events (irAEs).

Main Results:

• Volrustomig demonstrated durable objective responses in patients with advanced cancers.
• Dose-dependent immune-related adverse events were observed, consistent with dual PD-1/CTLA-4 blockade.
• The bispecific format's impact on the therapeutic index requires further investigation.

Conclusions:

• Volrustomig shows potential as a novel immunotherapy agent for cancer treatment.
• Careful dose management is crucial to mitigate irAEs associated with volrustomig.
• Further studies are warranted to optimize volrustomig dosing and patient selection for improved therapeutic outcomes.